[Skip to Content]
[Skip to Content Landing]
February 1994

Does Wavelength Matter When Photocoagulating Eyes With Macular Degeneration or Diabetic Retinopathy?

Author Affiliations

Milan, Italy

Arch Ophthalmol. 1994;112(2):156-157. doi:10.1001/archopht.1994.01090140030009

We enjoyed reading the editorial by Bressler1 concerning the choice of the best laser wave-length to use in treating eyes affected with macular degeneration and diabetic retinopathy. The author presents bibliographic and clinical data that ophthalmologists can use to choose the best laser wavelength. In reference to infrared radiation for the treatment of proliferative diabetic retinopathy, Bressler concludes that "Although some clinicians have begun using the diode laser for such treatment, no direct comparisons of the therapeutic efficacy of infrared laser compared with visible light laser have been reported, to my knowledge."

We felt the same need for a comparative study some years ago when we started to use diode laser for treating diabetic patients affected with proliferative retinopathy. For this reason, we carried out a study2 in which 26 eyes of 24 diabetic patients affected with proliferative retinopathy were randomly assigned to argon-green or diode laser panretinal